Workflow
中达安(300635) - 2024 Q1 - 季度财报(更正)
SinoDaanSinoDaan(SZ:300635)2024-07-22 12:02

Financial Performance - The company's operating revenue for Q1 2024 was CNY 162,237,489.94, representing a 23.86% increase compared to CNY 130,988,151.85 in the same period last year[26]. - Net profit attributable to shareholders of the listed company decreased significantly to CNY 525,190.94, down 95.01% from CNY 10,517,071.90 year-on-year[26]. - The net profit after deducting non-recurring gains and losses was CNY 594,197.25, a decrease of 94.21% compared to CNY 10,258,878.30 in the previous year[26]. - The total comprehensive income for the period was CNY 2,072,172.57, compared to CNY 12,153,190.24 in the previous period, indicating a significant decline[57]. - Basic earnings per share decreased to CNY 0.0039, down 94.94% from CNY 0.0771 year-on-year[26]. - Total comprehensive income attributable to the parent company's owners was CNY 525,190.94, compared to CNY 10,517,071.90 in the previous period, indicating a significant decrease[57]. Cash Flow - The net cash flow from operating activities was CNY -28,231,963.45, an improvement of 5.71% compared to CNY -29,942,874.89 in the same period last year[26]. - Cash inflows from operating activities totaled CNY 160,776,551.52, an increase from CNY 142,641,135.11 in the previous period, reflecting a growth of approximately 12.5%[57]. - Cash received from the sale of goods and services was CNY 156,510,382.30, compared to CNY 131,462,372.00 in the previous period, representing an increase of about 19.0%[57]. - The net cash flow from financing activities surged to ¥18,909,472.54 from -¥7,124,593.26, an increase of 365.41%[31]. - Investment activities generated a net cash flow of -$8.62 million, compared to -$11.81 million in the previous period[45]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,275,679,872.10, an increase of 2.55% from CNY 1,243,900,445.90 at the end of the previous year[26]. - Long-term borrowings rose to ¥123,684,595.05 from ¥86,033,244.34, an increase of 43.76%[29]. - The total accounts receivable increased to ¥152,682,620.16 from ¥134,177,078.45, reflecting a growth of approximately 13.5%[18]. - Inventory rose to ¥405,475.81, a 36.6% increase compared to ¥296,840.85 from the previous year[9]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,045, indicating a stable shareholder base[12]. - The largest shareholder, Jinan Likong Disen Equity Investment Partnership, holds 10.29% of the shares, totaling 14,031,261 shares[12]. Operational Highlights - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[3]. - The company confirmed no non-recurring gains or losses were reported during the quarter[6]. - The company has not indicated any significant mergers or acquisitions in the current reporting period[3]. Expenses and Investments - The total operating costs increased to ¥168,257,201.66 from ¥141,234,201.59, reflecting a rise of 19.14%[40]. - Research and development expenses increased to $13.40 million, up from $10.32 million year-over-year[56]. - The company reported a significant increase in management expenses to $22.41 million from $22.32 million in the previous period[56]. - The company reported a significant increase in other expenses, with non-operating expenses rising to ¥426,632.03 from ¥9,682.42, a change of 4306.25%[29]. Future Plans and Changes - The company plans to repurchase shares amounting to no more than ¥7.2 million and no less than ¥3.6 million within six months starting from February 7, 2024[34]. - The company has decided to terminate the issuance of shares to specific targets due to changes in the financing market environment[36]. - The company is set to implement new accounting standards starting in 2024, which may impact future financial reporting[59]. - The audit report for the first quarter of 2024 is available, providing insights into the company's financial health[59].